{
    "Age": "UNKNOWN",
    "Date": "UNKNOWN",
    "Extract Text": "APOLLO PROHEALTH SUPER YEAR 1\n\nNAME RESULT BIOLOGICAL REFERENCE INTERVALS UNITS\nGLUCOSE - PLASMA (FASTING) 129 * <=99 mg/dL\n(Hexokinase-endpoint) Increase risk of diabetes(impaired\nfasting Glucose) 100-125,\nDiabetic>=126\nGLYCOSYLATED HEMOGLOBIN (HBA1C) - WHOLE BLOOD 6.8 * Normal < 5.7% %\nGLYCOSYLATED HEMOGLOBIN (HBA1C) - Increased risk for Diabetes 5.7 -\nWHOLE BLOOD (for Exchange High 6.4%,\nPerformance Liquid Chromatography - NGSP Diabetes >= 6.5%\ncertified)\nUREA - SERUM / PLASMA 27 13 - 43 mg/dL\n(UREASE-GLDH-UV)\nCREATININE - SERUM / PLASMA 1.2 Male: 0.9 - 1.3 mg/dL\n(Jaffe Alkaline Picrate Kinetic/IDMS standardisation)\nURIC ACID - SERUM / PLASMA 8.2 * Male: 3.5 - 7.2 mg/dL\n(URICASE/PEROXIDASE)\nCHOLESTEROL - SERUM / PLASMA 214 * Desirable: <200 mg/dL\n(Enzymatic Method) Borderline High: 200 - 239\nHigh: >=240\nHDL CHOLESTEROL - SERUM / PLASMA 40 Low: <40 mg/dL\n(Direct measure.Polymer-polyanion) Desirable: >=40\nLDL CHOLESTEROL - SERUM / PLASMA (DIRECT 154 * Desirable: <=130 mg/dL\nLDL) Borderline High: 130 - 159\n(Direct Measurement) High: 160 - 189\nVery High: >=190\nTRIGLYCERIDES - SERUM / PLASMA 190 * Desirable: <150 mg/dL\n(GLYCEROL 3 PHOSPHATE OXIDASE - GPO) Borderline High: 150 - 199\nHigh: 200-500\nVery High: >=500\nTOTAL CHOLESTEROL/HDL CHOLESTEROL 5.4 * < 4.5\n\nRatio(Calculated)\n(This parameter is not in the scope of NABL\naccreditation)\nBILIRUBIN - TOTAL - SERUM 0.6 0.0 - 1.3 mg/dL\n(Diazonium Salt) (This test is not under the\nscope of NABL)\nBILIRUBIN CONJUGATED (DIRECT) - SERUM 0.2 0.0 - 0.5 mg/dL\n(Diazo Reaction) (This test is not under the\nscope of NABL)\nBILIRUBIN UNCONJUGATED - SERUM 0.4 0.0 - 1.2 mg/dL\n(Calculated) (This parameter is not in the scope\nof NABL accreditation)\nPROTEIN - TOTAL - SERUM 6.8 Ambulatory: 6.4 - 8.3 g/dL\n(Biuret) Recumbent: 6.0 -7.8\nALBUMIN - SERUM 4.4 20 - 60 Yr: 3.5 - 5.2 g/dL\n(BCC)\nGLOBULIN - SERUM:(Calculated) 2.4 2.0 - 3.5 g/dL\n(This parameter is not in the scope of NABL\naccreditation)\nAST (SGOT) - SERUM 21 Male: <35 U/L\n(Without P5P)\nALT (SGPT) - SERUM 23 Male: <45 U/L\n(UV without P5P)\nGGTP - GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM 28 Male: < 64 U/L\n(L - Gamma - Glutamyl - 3 Carboxy - 4\nnitroanilide)\nALKALINE PHOSPHATASE - SERUM 126 <128 U/L\n(PNPP.AMP buffer.Kinetic)\n\nReport Status:Final\n* END OF REPORT *",
    "Gender": "UNKNOWN",
    "Patient Name": "UNKNOWN",
    "Summary": "Medical report processed successfully. Please refer to the extracted text for details.",
    "extracted_text": "APOLLO PROHEALTH SUPER YEAR 1\n\nNAME RESULT BIOLOGICAL REFERENCE INTERVALS UNITS\nGLUCOSE - PLASMA (FASTING) 129 * <=99 mg/dL\n(Hexokinase-endpoint) Increase risk of diabetes(impaired\nfasting Glucose) 100-125,\nDiabetic>=126\nGLYCOSYLATED HEMOGLOBIN (HBA1C) - WHOLE BLOOD 6.8 * Normal < 5.7% %\nGLYCOSYLATED HEMOGLOBIN (HBA1C) - Increased risk for Diabetes 5.7 -\nWHOLE BLOOD (for Exchange High 6.4%,\nPerformance Liquid Chromatography - NGSP Diabetes >= 6.5%\ncertified)\nUREA - SERUM / PLASMA 27 13 - 43 mg/dL\n(UREASE-GLDH-UV)\nCREATININE - SERUM / PLASMA 1.2 Male: 0.9 - 1.3 mg/dL\n(Jaffe Alkaline Picrate Kinetic/IDMS standardisation)\nURIC ACID - SERUM / PLASMA 8.2 * Male: 3.5 - 7.2 mg/dL\n(URICASE/PEROXIDASE)\nCHOLESTEROL - SERUM / PLASMA 214 * Desirable: <200 mg/dL\n(Enzymatic Method) Borderline High: 200 - 239\nHigh: >=240\nHDL CHOLESTEROL - SERUM / PLASMA 40 Low: <40 mg/dL\n(Direct measure.Polymer-polyanion) Desirable: >=40\nLDL CHOLESTEROL - SERUM / PLASMA (DIRECT 154 * Desirable: <=130 mg/dL\nLDL) Borderline High: 130 - 159\n(Direct Measurement) High: 160 - 189\nVery High: >=190\nTRIGLYCERIDES - SERUM / PLASMA 190 * Desirable: <150 mg/dL\n(GLYCEROL 3 PHOSPHATE OXIDASE - GPO) Borderline High: 150 - 199\nHigh: 200-500\nVery High: >=500\nTOTAL CHOLESTEROL/HDL CHOLESTEROL 5.4 * < 4.5\n\nRatio(Calculated)\n(This parameter is not in the scope of NABL\naccreditation)\nBILIRUBIN - TOTAL - SERUM 0.6 0.0 - 1.3 mg/dL\n(Diazonium Salt) (This test is not under the\nscope of NABL)\nBILIRUBIN CONJUGATED (DIRECT) - SERUM 0.2 0.0 - 0.5 mg/dL\n(Diazo Reaction) (This test is not under the\nscope of NABL)\nBILIRUBIN UNCONJUGATED - SERUM 0.4 0.0 - 1.2 mg/dL\n(Calculated) (This parameter is not in the scope\nof NABL accreditation)\nPROTEIN - TOTAL - SERUM 6.8 Ambulatory: 6.4 - 8.3 g/dL\n(Biuret) Recumbent: 6.0 -7.8\nALBUMIN - SERUM 4.4 20 - 60 Yr: 3.5 - 5.2 g/dL\n(BCC)\nGLOBULIN - SERUM:(Calculated) 2.4 2.0 - 3.5 g/dL\n(This parameter is not in the scope of NABL\naccreditation)\nAST (SGOT) - SERUM 21 Male: <35 U/L\n(Without P5P)\nALT (SGPT) - SERUM 23 Male: <45 U/L\n(UV without P5P)\nGGTP - GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM 28 Male: < 64 U/L\n(L - Gamma - Glutamyl - 3 Carboxy - 4\nnitroanilide)\nALKALINE PHOSPHATASE - SERUM 126 <128 U/L\n(PNPP.AMP buffer.Kinetic)\n\nReport Status:Final\n* END OF REPORT *"
}